Defilade Capital Management’s AbbVie ABBV Stock Holding History

Defilade Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-227,669	Closed	-$52M	–	32
2025 Q4	$52M	Buy	+227,669	New	+$51.9M	7.05%	2

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Defilade Capital Management's ABBV Position: Q1 2026 in Review

Defilade Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 227,669 shares — an estimated $52M sold.

Defilade Capital Management first reported a position in ABBV in Q4 2025 and held it in 1 quarter. The position peaked at $52M in Q4 2025. 4,101 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Defilade Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Defilade Capital Management sold 227,669 AbbVie shares in Q1 2026, an estimated $52M.
Defilade Capital Management first reported a position in AbbVie in Q4 2025 and held it in 1 quarter.
Defilade Capital Management's AbbVie position peaked at $52M in Q4 2025.
4,101 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.